0 16 Characterization characterization NN 17 19 of of IN 20 23 the the DT 24 31 nuclear nuclear JJ 32 35 and and CC 36 47 cytoplasmic cytoplasmic JJ 48 58 components component NNS 59 61 of of IN 62 65 the the DT 66 83 lymphoid-specific lymphoid-specific JJ 84 91 nuclear nuclear JJ 92 98 factor factor NN 99 101 of of IN 102 111 activated activate VBN 112 113 T t NN 114 119 cells cell NNS 120 121 ( ( ( 121 126 NF-AT NF-AT NNP 126 127 ) ) ) 128 135 complex complex NN 135 136 . . . 138 141 The the DT 142 159 lymphoid-specific lymphoid-specific JJ 160 173 transcription transcription NN 174 181 complex complex NN 181 182 , , , 183 188 NF-AT NF-AT NNP 188 189 , , , 190 192 is be VBZ 193 201 involved involve VBN 202 204 in in IN 205 210 early early JJ 211 215 gene gene NN 216 226 activation activation NN 227 229 in in IN 230 231 T t NN 232 237 cells cell NNS 238 241 and and CC 242 244 is be VBZ 245 254 assembled assemble VBN 255 259 from from IN 260 261 a a DT 262 274 pre-existing pre-existing JJ 274 275 , , , 276 277 T t NN 278 282 cell cell NN 283 293 restricted restricted JJ 294 305 cytoplasmic cytoplasmic JJ 306 312 factor factor NN 313 316 and and CC 317 319 an an DT 320 329 inducible inducible JJ 330 340 ubiquitous ubiquitous JJ 341 348 nuclear nuclear JJ 349 358 component component NN 359 365 within within IN 366 368 30 30 CD 369 372 min min NN 373 378 after after IN 379 389 activation activation NN 390 397 through through IN 398 401 the the DT 402 409 antigen antigen NN 410 418 receptor receptor NN 418 419 . . . 420 426 Recent recent JJ 427 434 studies study NNS 435 439 have have VBP 440 450 implicated implicate VBN 451 454 the the DT 455 461 family family NN 462 464 of of IN 465 468 AP1 ap1 NN 469 476 factors factor NNS 477 479 as as IN 480 490 components component NNS 491 493 of of IN 494 497 the the DT 498 504 murine murine JJ 505 510 NF-AT nf-at NN 511 518 complex complex NN 518 519 . . . 520 528 Evidence evidence NN 529 531 is be VBZ 532 540 provided provide VBN 541 545 here here RB 546 550 that that IN 551 554 the the DT 555 562 nuclear nuclear JJ 563 572 component component NN 573 575 of of IN 576 581 human human JJ 582 587 NF-AT nf-at NN 588 596 contains contain VBZ 597 600 the the DT 601 608 phorbol phorbol NN 609 624 ester-inducible ester-inducible JJ 625 638 transcription transcription NN 639 645 factor factor NN 646 649 AP1 AP1 NNP 650 651 ( ( ( 651 658 Jun/Fos Jun/Fos NNP 658 659 ) ) ) 659 660 . . . 661 663 We we PRP 664 671 further further RB 672 684 characterize characterize VBP 685 690 which which WDT 691 694 AP1 ap1 NN 695 701 family family NN 702 709 members member NNS 710 713 can can MD 714 720 assume assume VB 721 725 this this DT 726 730 role role NN 730 731 . . . 732 740 Antisera Antiserum NNP 741 743 to to TO 744 747 Fos Fos NNP 748 756 inhibits inhibit VBZ 757 762 NF-AT NF-AT NNP 763 766 DNA DNA NNP 767 774 binding binding NN 775 777 as as IN 778 782 does do VBZ 783 785 an an DT 786 801 oligonucleotide oligonucleotide NN 802 812 containing contain VBG 813 814 a a DT 815 822 binding bind VBG 823 827 site site NN 828 831 for for IN 832 835 AP1 AP1 NNP 835 836 . . . 837 849 Constitutive constitutive JJ 850 860 expression expression NN 861 863 in in FW 864 868 vivo vivo FW 869 871 of of IN 872 875 Fos Fos NNP 875 876 , , , 877 880 and and CC 881 883 to to TO 884 885 a a DT 886 892 lesser less JJR 893 899 extent extent NN 900 905 Fra-1 fra-1 NN 905 906 , , , 907 917 eliminates eliminate VBZ 918 921 the the DT 922 933 requirement requirement NN 934 937 for for IN 938 945 phorbol phorbol NN 946 958 12-myristate 12-myristate NN 959 969 13-acetate 13-acetate NN 970 971 ( ( ( 971 974 PMA PMA NNP 974 975 ) ) ) 976 987 stimulation stimulation NN 987 988 , , , 989 996 leaving leave VBG 997 1011 NF-AT-directed nf-at-directed JJ 1012 1025 transcription transcription NN 1026 1036 responsive responsive JJ 1037 1039 to to TO 1040 1047 calcium calcium NN 1048 1057 ionophore ionophore NN 1058 1063 alone alone RB 1063 1064 . . . 1065 1079 Overexpression overexpression NN 1080 1082 of of IN 1083 1087 cJun cjun NN 1088 1090 or or CC 1091 1095 JunD JunD NNP 1095 1096 , , , 1097 1100 but but CC 1101 1104 not not RB 1105 1109 JunB JunB NNP 1109 1110 , , , 1111 1115 also also RB 1116 1126 eliminates eliminate VBZ 1127 1130 the the DT 1131 1142 requirement requirement NN 1143 1146 for for IN 1147 1150 PMA PMA NNP 1150 1151 , , , 1152 1162 indicating indicate VBG 1163 1167 that that IN 1168 1172 many many JJ 1173 1176 but but CC 1177 1180 not not RB 1181 1184 all all DT 1185 1189 Jun- jun- NN 1190 1193 and and CC 1194 1205 Fos-related fos-related JJ 1206 1214 proteins protein NNS 1215 1227 functionally functionally RB 1228 1236 activate activate VBP 1237 1252 NF-AT-dependent nf-at-dependent JJ 1253 1266 transcription transcription NN 1267 1269 in in IN 1270 1273 the the DT 1274 1282 presence presence NN 1283 1285 of of IN 1286 1289 the the DT 1290 1301 cytoplasmic cytoplasmic JJ 1302 1311 component component NN 1311 1312 . . . 1313 1318 NF-AT NF-AT NNP 1319 1322 DNA DNA NNP 1323 1330 binding binding NN 1331 1334 can can MD 1335 1337 be be VB 1338 1351 reconstituted reconstitute VBN 1352 1354 in in FW 1355 1360 vitro vitro FW 1361 1366 using use VBG 1367 1380 semi-purified semi-purified JJ 1381 1384 AP1 ap1 NN 1385 1393 proteins protein NNS 1394 1399 mixed mix VBN 1400 1404 with with IN 1405 1412 cytosol cytosol NN 1413 1417 from from IN 1418 1419 T t NN 1420 1431 lymphocytes lymphocyte NNS 1431 1432 . . . 1433 1436 Fos Fos NNP 1437 1445 proteins protein NNS 1446 1449 are be VBP 1450 1453 not not RB 1454 1460 needed need VBN 1461 1464 for for IN 1465 1469 this this DT 1470 1484 reconstitution reconstitution NN 1484 1485 , , , 1486 1489 and and CC 1490 1498 although although IN 1499 1503 JunB JunB NNP 1504 1506 is be VBZ 1507 1510 not not RB 1511 1521 functional functional JJ 1521 1522 , , , 1523 1525 it it PRP 1526 1529 can can MD 1530 1541 participate participate VB 1542 1544 in in IN 1545 1548 the the DT 1549 1554 NF-AT NF-AT NNP 1555 1558 DNA DNA NNP 1559 1566 binding binding NN 1567 1574 complex complex NN 1574 1575 . . . 1576 1583 Finally finally RB 1583 1584 , , , 1585 1587 we we PRP 1588 1592 have have VBP 1593 1602 partially partially RB 1603 1611 purified purify VBN 1612 1615 the the DT 1616 1627 cytoplasmic cytoplasmic JJ 1628 1637 component component NN 1638 1640 of of IN 1641 1646 NF-AT NF-AT NNP 1647 1650 and and CC 1651 1655 show show NN 1656 1658 by by IN 1659 1666 elution elution NN 1667 1670 and and CC 1671 1683 renaturation renaturation NN 1684 1688 from from IN 1689 1707 SDS-polyacrylamide SDS-polyacrylamide NNP 1708 1711 gel gel NN 1712 1727 electrophoresis electrophoresis NN 1728 1732 gels gel NNS 1733 1737 that that IN 1738 1740 it it PRP 1741 1744 has have VBZ 1745 1746 a a DT 1747 1756 molecular molecular JJ 1757 1761 mass mass NN 1762 1769 between between IN 1770 1772 94 94 CD 1773 1776 and and CC 1777 1780 116 116 CD 1781 1784 kDa kda NN 1785 1788 and and CC 1789 1792 may may MD 1793 1797 have have VB 1798 1806 multiple multiple JJ 1807 1821 differentially differentially RB 1822 1830 modified modified JJ 1831 1836 forms form NNS 1836 1837 . . .